In vivo mutant frequency rises among breast cancer patients after exposure to high doses of gamma-radiation

Human in vivo mutant frequencies can be measured by cloning freshly isolated lymphocytes in selective media containing 6-thioguanine (TG). This method was applied to monitoring environmental mutagenesis, by studying lymphocytes separated from peripheral blood of 12 cancer patients undergoing radiotherapy. Before therapy, cancer patients had an average 8.6 X 10(-6) mutants/cell, compared to 2.4 X 10(-6) mutants/cell for heart patients and 1.1 X 10(-6) mutants/cell for healthy controls. After exposure of cancer patients to 50 Gy of gamma-radiation delivered to the treated area, or an estimated 4 Gy received by each lymphocyte, patients averaged 36.8 X 10(-6) mutants/viable cell.